^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    AVENIO Tumor Tissue Surveillance Kit

    Company:
    Roche
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    almost3years
    Detection of minimal residual disease (MRD) in colorectal cancer (CRC) patients UICC stage II/III by ultra-deep sequencing of cfDNA from post-surgery plasma. (ASCO-GI 2022)
    Even in this small cohort of CRC UICC stage II/III patients, MRD detection in post-surgery plasma is the strongest predictor of shorter time to progression. Ultra-deep sequencing of cfDNA samples did not influence MRD detection on a patient-level. *for Research Use Only; not for use in diagnostic procedures.
    Clinical • Minimal residual disease
    |
    AVENIO Tumor Tissue Surveillance Kit • AVENIO ctDNA Surveillance Kit
    over4years
    [VIRTUAL] Concordance between treatment-naive tissue and circulating tumour DNA (ctDNA) in late stage non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) (ESMO 2020)
    "Legal entity responsible for the study: Roche Sequencing Solutions, Inc. Funding: Roche Sequencing Solutions, Inc."
    KIT mutation
    |
    AVENIO Tumor Tissue Surveillance Kit • AVENIO ctDNA Surveillance Kit